Nitric oxide synthases, S-nitrosylation and cardiovascular health: From molecular mechanisms to therapeutic opportunities (Review)

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 1555-1565

  Treuer, Adriana V ^a   Gonzalez, Daniel R ^a  

^a UNIVERSIDAD DE TALCA   (Chile)

Author keywords

Cardiovascular; Heart; Nitric oxide synthase; S nitrosylation

Indexed keywords

GUANYLATE CYCLASE; HEMOGLOBIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE NITROGEN SPECIES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S NITROSOTHIOL; SUPEROXIDE; XANTHINE OXIDASE;

ANGIOGENESIS; BIOLOGICAL ACTIVITY; BLOOD VESSEL TONE; CARDIOMYOPATHY; CARDIOVASCULAR SYSTEM; CATABOLISM; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CIRCULATION; DISEASE ASSOCIATION; DUCHENNE MUSCULAR DYSTROPHY; EMBRYONIC STEM CELL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENTEROVIRUS INFECTION; ENZYME ACTIVATION; HEALTH STATUS; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; MOLECULAR BIOLOGY; NITROSATION; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION STATE; PREECLAMPSIA; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; REACTION ANALYSIS; REGULATORY MECHANISM; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; VIRUS MYOCARDITIS; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; CARDIOMEGALY; CARDIOVASCULAR DISEASES; ENDOTHELIUM CELL; HEART VENTRICLE REMODELING; METABOLISM; OXIDATION REDUCTION REACTION; STEM CELL;

ANIMALS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELIAL CELLS; HEART FAILURE; HUMANS; INFLAMMATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATION-REDUCTION; REACTIVE NITROGEN SPECIES; STEM CELLS; VENTRICULAR REMODELING;

EID: 84916606571     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2968     Document Type: Review

References (145)

1. Stamler JS, Toone EJ, Lipton SA and Sucher NJ: (S)NO signals: translocation, regulation, and a consensus motif. Neuron 18: 691-696, 1997.
2. Stamler JS, Lamas S and Fang FC: Nitrosylation. the prototypic redox-based signaling mechanism. Cell 106: 675-683, 2001.
3. Beigi F, Gonzalez DR, Minhas KM, Sun QA, Foster MW, Khan SA, Treuer AV, Dulce RA, Harrison RW, Saraiva RM, Premer C, Schulman IH, Stamler JS and Hare JM:. Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function. Proc Natl Acad Sci USA 109: 4314-4319, 2012.
4. Anand P, Stamler JS: Enzymatic mechanisms regulating protein S-nitrosylation: implications in health and disease. J Mol Med (Berl) 90: 233-244, 2012.
5. van der Vliet A, Hoen PA, Wong PS, Bast A and Cross CE: Formation of S-nitrosothiols via direct nucleophilic nitrosation of thiols by peroxynitrite with elimination of hydrogen peroxide J Biol Chem 273: 30255-30262, 1998.
6. Espey MG, Thomas DD, Miranda KM and Wink DA: Focusing of nitric oxide mediated nitrosation and oxidative nitrosylation as a consequence of reaction with superoxide. Proc Natl Acad Sci USA 99: 11127-11132, 2002.
7. Espey MG, Miranda KM, Thomas DD, Xavier S, Citrin D, Vitek MP and Wink DA: A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species. Ann N Y Acad Sci 962: 195-206, 2002.
8. Hogg N: The kinetics of S-transnitrosation ? a reversible second-order reaction. Anal Biochem 272: 257-262, 1999.
9. Kharitonov VG, Sundquist AR and Sharma VS: Kinetics of nitrosation of thiols by nitric oxide in the presence of oxygen. J Biol Chem 270: 28158-28164, 1995.
10. Liu L, Hausladen A, Zeng M, Que L, Heitman J and Stamler JS: A metabolic enzyme for Snitrosothiol conserved from bacteria to humans. Nature 410: 490-494, 2001.
11. Liu L, Yan Y, Zeng M, et al: Essential roles of Snitrosothiols in vascular homeostasis and endotoxic shock. Cell 116: 617-628, 2004.
12. Pawloski JR, Hess DT and Stamler JS: Export by red blood cells of nitric oxide bioactivity. Nature 409: 622-626, 2001.
13. Singel DJ and Stamler JS: Chemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and Snitrosohemoglobin. Annu Rev Physiol 67: 99-145, 2005.
14. Bellamy TC and Garthwaite J: The receptor-like properties of nitric oxide-activated soluble guanylyl cyclase in intact cells. Mol Cell Biochem 230: 165-176, 2002.
15. Bellamy TC, Wood J and Garthwaite J: On the activation of soluble guanylyl cyclase by nitric oxide. Proc Natl Acad Sci USA 99: 507-510, 2002.
16. Gewaltig MT and Kojda G: Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55: 250-260, 2002.
17. Rochais F, Vandecasteele G, Lefebvre F, et al: Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels. J Biol Chem 279: 52095-52105, 2004.
18. Closs EI, Simon A, Vékony N and Rotmann A: Plasma membrane transporters for arginine. J Nutr 134 (Suppl 10): 2752S-2759S and 27655-27675, 2004.
19. Mann GE, Yudilevich DL and Sobrevia L: Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83: 183-252, 2003.
20. Flam BR, Hartmann PJ, Harrell-Booth M, Solomonson LP and Eichler DC: Caveolar localization of arginine regeneration enzymes, argininosuccinate synthase, and lyase, with endothelial nitric oxide synthase. Nitric Oxide 5: 187-197, 2001.
21. Steppan J, Ryoo S, Schuleri KH, et al: Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism. Proc Natl Acad Sci USA 103: 4759-4764, 2006.
22. Gellman J, Hare JM, Lowenstein CJ, et al: L-arginine ameliorates the abnormal sympathetic response of the dysfunctional human coronary microvasculature. Angiology 55: 1-8, 2004.
23. Casanello P and Sobrevia L: Intrauterine growth retardation is associated with reduced activity and expression of the cationic amino acid transport systems y+/hCAT-1 and y+/hCAT-2B and lower activity of nitric oxide synthase in human umbilical vein endothelial cells. Circ Res 91: 127-134, 2002.
24. Berkowitz DE, White R, Li D, et al: Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108: 2000-2006, 2003.
25. Topal G, Brunet A, Walch L, Boucher JL and David-Dufilho M: Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells. J Pharmacol Exp Ther 318: 1368-1374, 2006.
26. Peluffo RD: L-Arginine currents in rat cardiac ventricular myocytes. J Physiol 580: 925-936, 2007.
27. Hao G, Xie L and Gross SS: Argininosuccinate synthetase is reversibly inactivated by S-nitrosylation in vitro and in vivo. J Biol Chem 279: 36192-36200, 2004.
28. Knipp M, Braun O, Gehrig PM, Sack R and Vasák M: Zn(II)-free dimethylargininase-1 (DDAH-1) is inhibited upon specific Cys-S-nitrosylation. J Biol Chem 278: 3410-3416, 2003.
29. Leiper J, Murray-Rust J, McDonald N and Vallance P: S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 99: 13527-13532, 2002.
30. Bauer PM, Buga GM, Fukuto JM, Pegg AE and Ignarro LJ: Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme. J Biol Chem 276: 34458-34464, 2001.
31. Figueroa XF, González DR, Martínez AD, Durán WN and Boric MP: ACh-induced endothelial NO synthase translocation, NO release and vasodilatation in the hamster microcirculation in vivo. J Physiol 544: 883-896, 2002.
32. Sánchez FA, Savalia NB, Durán RG, Lal BK, Boric MP and Durán WN: Functional significance of differential eNOS translocation. Am J Physiol Heart Circ Physiol 291: H1058-H1064, 2006.
33. Icking A, Matt S, Opitz N, Wiesenthal A, Müller-Esterl W and Schilling K: NOSTRIN functions as a homotrimeric adaptor protein facilitating internalization of eNOS. J Cell Sci 118: 5059-5069, 2005.
34. Dedio J, König P, Wohlfart P, Schroeder C, Kummer W and Müller-Esterl W: NOSIP, a novel modulator of endothelial nitric oxide synthase activity. FASEB J 15: 79-89, 2001.
35. König P, Dedio J, Oess S, Papadakis T, Fischer A, Müller-Esterl W and Kummer W: NOSIP and its interacting protein, eNOS, in the rat trachea and lung. J Histochem Cytochem 53: 155-164, 2005.
36. Schleicher M, Brundin F, Gross S, Müller-Esterl W and Oess S: Cell cycle-regulated inactivation of endothelial NO synthase through NOSIP-dependent targeting to the cytoskeleton. Mol Cell Biol 25: 8251-8258, 2005.
37. Erwin PA, Lin AJ, Golan DE and Michel T: Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 280: 19888-19894, 2005.
38. Erwin PA, Mitchell DA, Sartoretto J, Marletta MA and Michel T: Subcellular targeting and differential S-nitrosylation of endothelial nitric-oxide synthase. J Biol Chem 281: 151-157, 2006.
39. Brixius K, Bloch W, Pott C, et al: Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol 143: 1014-1022, 2004.
40. Pott C, Steinritz D, Bölck B, Mehlhorn U, Brixius K, Schwinger RH and Bloch W: eNOS translocation but not eNOS phosphorylation is dependent on intracellular Ca2+ in human atrial myocardium. Am J Physiol Cell Physiol 290: C1437-C1445, 2006.
41. Iwakiri Y, Satoh A, Chatterjee S, et al: Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci USA 103: 19777-19782, 2006.
42. Matsushita K, Morrell CN, Cambien B, et al: Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 115: 139-150, 2003.
43. Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM and Dimmeler S: Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol 4: 743-749, 2002.
44. Ravi K, Brennan LA, Levic S, Ross PA and Black SM: S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc Natl Acad Sci USA 101: 2619-2624, 2004.
45. Segal SS, Brett SE and Sessa WC: Codistribution of NOS and caveolin throughout peripheral vasculature and skeletal muscle of hamsters. Am J Physiol 277: H1167-H1177, 1999.
46. Silvagno F, Xia H and Bredt DS: Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. J Biol Chem 271: 11204-11208, 1996.
47. Schuh K, Uldrijan S, Telkamp M, Rothlein N and Neyses L: The plasmamembrane calmodulin-dependent calcium pump: a major regulator of nitric oxide synthase I. J Cell Biol 155: 201-205, 2001.
48. Oceandy D, Cartwright EJ, Emerson M, et al: Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation 115: 483-492, 2007.
49. Williams JC, Armesilla AL, Mohamed TM, et al: The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J Biol Chem 281: 23341-23348, 2006.
50. Barouch LA, Harrison RW, Skaf MW, et al: Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416: 337-339, 2002.
51. Khan SA, Lee K, Minhas KM, et al: Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci USA 101: 15944-15948, 2004.
52. Ziolo MT, Maier LS, Piacentino V III, Bossuyt J, Houser SR and Bers DM: Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing Ca2+ transients. Circulation 109: 1886-1891, 2004.
53. Zhu X, Bernecker OY, Manohar NS, et al: Increased leakage of sarcoplasmic reticulum Ca2+ contributes to abnormal myocyte Ca2+ handling and shortening in sepsis. Crit Care Med 33: 598-604, 2005.
54. Gonzalez DR, Treuer AV, Castellanos J, Dulce RA and Hare JM: Impaired Snitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J Biol Chem 285: 28938-28945, 2010.
55. Chao DS, Gorospe JR, Brenman JE, et al: Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med 184: 609-618, 1996.
56. Bia BL, Cassidy PJ, Young ME, et al: Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 31: 1857-1862, 1999.
57. Williams IA and Allen DG: Intracellular calcium handling in ventricular myocytes from mdx mice. Am Physiol Heart Circ Physiol 292: H846-H855, 2007.
58. Sapp JL, Bobet J and Howlett SE: Contractile properties of myocardium are altered in dystrophin-deficient mdx mice. J Neurol Sci 142: 17-24, 1996.
59. Tidball JG and Wehling-Henricks M: The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 102 (1985): 1677-1686, 2007.
60. Wehling-Henricks M, Jordan MC, Roos KP, Deng B and Tidball JG: Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 14: 1921-1933, 2005.
61. Badorff C and Knowlton KU: Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol 193: 121-126, 2004.
62. Zaragoza C, Ocampo CJ, Saura M, McMillan A and Lowenstein CJ: Nitric oxide inhibition of coxsackievirus replication in vitro. J Clin Invest 100: 1760-1767, 1997.
63. Zaragoza C, Ocampo C, Saura M, et al: The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proc Natl Acad Sci USA 95: 2469-2474, 1998.
64. Zell R, Markgraf R, Schmidtke M, et al: Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Med Microbiol Immunol 193: 91-100, 2004.
65. Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980.
66. Poteser M, Romanin C, Schreibmayer W, Mayer B and Groschner K: Snitrosation controls gating and conductance of the alpha 1 subunit of class C L-type Ca(2+) channels. J Biol Chem 276: 14797-14803, 2001.
67. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schöneich C and Cohen RA: S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 10: 1200-1207, 2004.
68. Carvajal JA, Germain AM, Huidobro-Toro JP and Weiner CP: Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 184: 409-420, 2000.
69. Alencar JL, Lobysheva I, Chalupsky K, Geffard M, Nepveu F, Stoclet JC and Muller B: Snitrosating nitric oxide donors induce long-lasting inhibition of contraction in isolated arteries. J Pharmacol Exp Ther 307: 152-159, 2003.
70. Nozik-Grayck E, Whalen EJ, Stamler JS, McMahon TJ, Chitano P and Piantadosi CA: Snitrosoglutathione inhibits alpha1-adrenergic receptor-mediated vasoconstriction and ligand binding in pulmonary artery. Am J Physiol Lung Cell Mol Physiol 290: L136-L143, 2006.
71. Shesely EG, Maeda N, Kim HS, et al: Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 93: 13176-13181, 1996.
72. Gamboa A and Biaggioni I: Response to contribution of endothelial nitric oxide to blood pressure in humans. Hypertension: 2007.
73. Kojda G and Harrison D: Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 43: 562-571, 1999.
74. Landmesser U, Spiekermann S, Dikalov S, et al: Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106: 3073-3078, 2002.
75. Landmesser U, Dikalov S, Price SR, et al: Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209, 2003.
76. McNally JS, Davis ME, Giddens DP, et al: Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285: H2290-H2297, 2003.
77. Doehner W, Schoene N, Rauchhaus M, et al: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105: 2619-2624, 2002.
78. Thengchaisri N, Hein TW, Wang W, Xu X, Li Z, Fossum TW and Kuo L: Upregulation of arginase by H2O2 impairs endothelium-dependent nitric oxide-mediated dilation of coronary arterioles. Arterioscler Thromb Vasc Biol 26: 2035-2042, 2006.
79. White AR, Ryoo S, Li D, et al: Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 47: 245-251, 2006.
80. Johnson FK, Johnson RA, Peyton KJ and Durante W: Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 288: R1057-R1062, 2005.
81. Ryoo S, Lemmon CA, Soucy KG, et al: Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 99: 951-960, 2006.
82. Ming XF, Barandier C, Viswambharan H, et al: Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110: 3708-3714, 2004.
83. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R and Zeiher AM: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605, 1999.
84. Dixit M, Loot AE., Mohamed A, Fisslthaler B, Boulanger CM, Ceacareanu B., Hassid A, Busse R and Fleming I: Gab1, SHP2, and protein kinase A are crucial for the activation of the endothelial NO synthase by fluid shear stress. Circ.Res 97: 1236-1244, 2005.
85. Jin ZG, Wong C, Wu J and Berk BC: Flow shear stress stimulates Gab1 tyrosine phosphorylation to mediate protein kinase B and endothelial nitric-oxide synthase activation in endothelial cells. J Biol.Chem 280: 12305-12309, 2005.
86. Sibai B, Dekker G and Kupferminc M: Preeclampsia. Lancet 365: 785-799, 2005.
87. Vatish M, Randeva HS and Grammatopoulos DK: Hormonal regulation of placental nitric oxide and pathogenesis of preeclampsia. Trends Mol Med 12: 223-233, 2006.
88. Germain AM, Romanik MC, Guerra I, et al: Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension 49: 90-95, 2007.
89. Noris M, Todeschini M, Cassis P, et al: Larginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 43: 614-622, 2004.
90. Buvinic S, Briones R and Huidobro-Toro JP: P2Y(1) and P2Y(2) receptors are coupled to the NO/cGMP pathway to vasodilate the rat arterial mesenteric bed. Br J Pharmacol 136: 847-856, 2002.
91. Myatt L and Cui X: Oxidative stress in the placenta. Histochem Cell Biol 122: 369-382, 2004.
92. Many A, Westerhausen-Larson A, Kanbour-Shakir A and Roberts JM: Xanthine oxidase/dehydrogenase is present in human placenta. Placenta 17: 361-365, 1996.
93. Many A and Roberts JM: Increased xanthine oxidase during labour ? implications for oxidative stress. Placenta 18: 725-726, 1997.
94. Telfer JF, Thomson AJ, Cameron IT, Greer IA and Norman JE: Expression of superoxide dismutase and xanthine oxidase in myometrium, fetal membranes and placenta during normal human pregnancy and parturition. Hum Reprod 12: 2306-2312, 1997.
95. Many A, Hubel CA, Fisher SJ, Roberts JM and Zhou Y: Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol 156: 321-331, 2000.
96. Raijmakers MT, Dechend R and Poston L: Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension 44: 374-380, 2004.
97. Kubes P, Suzuki M and Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88: 4651-4655, 1991.
98. Rondaij MG, Bierings R, Kragt A, van Mourik JA and Voorberg J: Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 26: 1002-1007, 2006.
99. Mehta D and Malik AB: Signaling mechanisms regulating endothelial permeability. Physiol Rev 86: 279-367, 2006.
100. Kubes P and Granger DN: Nitric oxide modulates microvascular permeability. Am J Physiol 262: H611-H615, 1992.
101. Bucci M, Roviezzo F, Posadas I, et al: Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc Natl Acad Sci USA 102: 904-908, 2005.
102. Fukumura D, Gohongi T, Kadambi A, et al: Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factorinduced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98: 2604-2609, 2001.
103. Hatakeyama T, Pappas PJ, Hobson RW II, Boric MP, Sessa WC and Durán WN: Endothelial nitric oxide synthase regulates microvascular hyperpermeability in vivo. J Physiol 574: 275-281, 2006.
104. Aramoto H, Breslin JW, Pappas PJ, Hobson RW II and Durán WN: Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation. Am J Physiol Heart Circ Physiol 287: H1590-H1598, 2004.
105. Breslin JW, Pappas PJ, Cerveira JJ, Hobson RW II and Durán WN: VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol 284: H92-H100, 2003.
106. Yu P, Hatakeyama T, Aramoto H, et al: Mitogenactivated protein kinases regulate plateletactivating factor-induced hyperpermeability. Microcirculation 12: 637-643, 2005.
107. Wakatsuki T, Schlessinger J and Elson EL: The biochemical response of the heart to hypertension and exercise. Trends Biochem Sci 29: 609-617, 2004.
108. Olson EN and Schneider MD: Sizing up the heart: development redux in disease. Genes Dev 17: 1937-1956, 2003.
109. Barouch LA, Cappola TP, Harrison RW, Crone JK, Rodriguez ER, Burnett AL and Hare JM: Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol 35: 637-644, 2003.
110. Cappola TP, Cope L, Cernetich A, et al: Deficiency of different nitric oxide synthase isoforms activates divergent transcriptional programs in cardiac hypertrophy. Physiol Genomics 14: 25-34, 2003.
111. Takimoto E, Champion HC, Li M, et al: Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115: 1221-1231, 2005.
112. Marshall HE and Stamler JS: Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 40: 1688-1693, 2001.
113. Reynaert NL, Ckless K, Korn SH, et al: Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci USA 101: 8945-8950, 2004.
114. Gupta S, Young D and Sen S: Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289: H20-H29, 2005.
115. Higuchi Y, Otsu K, Nishida K, et al: Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 34: 233-240, 2002.
116. Hattori Y, Kasai K and Gross SS: NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Cardiovasc Res 63: 31-40, 2004.
117. Marshall HE, Merchant K and Stamler JS: Nitrosation and oxidation in the regulation of gene expression. FASEB J 14: 1889-1900, 2000.
118. Ichinose F, Bloch KD, Wu JC, Hataishi R, Aretz HT, Picard MH and Scherrer-Crosbie M: Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 286: H1070-H1075, 2004.
119. Togashi H, Sasaki M, Frohman E, Taira E, Ratan RR, Dawson TM and Dawson VL: Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci USA 94: 2676-2680, 1997.
120. Qu XW, Wang H, De Plaen IG, Rozenfeld RA and Hsueh W: Neuronal nitric oxide synthase (NOS) regulates the expression of inducible NOS in rat small intestine via modulation of nuclear factor kappa B. FASEB J 15: 439-446, 2001.
121. Li JM, Gall NP, Grieve DJ, Chen M and Shah AM: Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40: 477-484, 2002.
122. Minhas KM, Saraiva RM, Schuleri KH, et al: Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 98: 271-279, 2006.
123. Zhang P, Xu X, Hu X, van Deel ED, Zhu G and Chen Y: Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 100: 1089-1098, 2007.
124. Hataishi R, Rodrigues AC, Morgan JG, et al: Nitric oxide synthase 2 and pressure-overload-induced left ventricular remodelling in mice. Exp Physiol 91: 633-639, 2006.
125. Saraiva RM, Minhas KM, Raju SV, et al: Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation 112: 3415-3422, 2005.
126. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S and Casadei B: nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation 112: 3729-3737, 2005.
127. Damy T, Ratajczak P, Robidel E, et al: Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats. FASEB J 17: 1934-1936, 2003.
128. Bendall JK, Damy T, Ratajczak P, et al: Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 110: 2368-2375, 2004.
129. Damy T, Ratajczak P, Shah AM, et al: Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 363: 1365-1367, 2004.
130. Sun J, Picht E, Ginsburg KS, Bers DM, Steenbergen C and Murphy E: Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury. Circ.Res 98: 403-411, 2006.
131. Burkard N, Rokita AG, Kaufmann SG, Hallhuber M, Wu R, Hu K, Hofmann U, Bonz A, Frantz S, Cartwright, EJ, L, Maier LS, Maier SK, Renne T, Schuh K and Ritter O: Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ.Res. 100: e32-e44, 2007.
132. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al: Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 104: 1286-1291, 2001.
133. Janssens S, Pokreisz P, Schoonjans L, et al: Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 94: 1256-1262, 2004.
134. Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R and Lefer DJ: Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA 100: 4891-4896, 2003.
135. Christoforou N and Gearhart JD: Stem cells and their potential in cell-based cardiac therapies. Prog Cardiovasc Dis 49: 396-413, 2007.
136. Kanno S, Kim PK, Sallam K, Lei J, Billiar TR and Shears LL II: Nitric oxide facilitates cardiomyogenesis in mouse embryonic stem cells. Proc Natl Acad Sci USA 101: 12277-12281, 2004.
137. Krumenacker JS, Katsuki S, Kots A and Murad F: Differential expression of genes involved in cGMP-dependent nitric oxide signaling in murine embryonic stem (ES) cells and ES cell-derived cardiomyocytes. Nitric Oxide 14: 1-11, 2006.
138. Mujoo K, Krumenacker JS, Wada Y and Murad F: Differential expression of nitric oxide signaling components in undifferentiated and differentiated human embryonic stem cells. Stem Cells Dev 15: 779-787, 2006.
139. Danalache BA, Paquin J, Donghao W, et al: Nitric oxide signaling in oxytocin-mediated cardiomyogenesis. Stem Cells 25: 679-688, 2007.
140. Gassanov N, Jankowski M, Danalache B, Wang D, Grygorczyk R, Hoppe UC and Gutkowska J: Arginine vasopressin-mediated cardiac differentiation: insights into the role of its receptors and nitric oxide signaling. J Biol Chem 282: 11255-11265, 2007.
141. Aicher A, Heeschen C, Mildner-Rihm C, et al: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370-1376, 2003.
142. Aicher A, Heeschen C and Dimmeler S: The role of NOS3 in stem cell mobilization. Trends Mol Med 10: 421-425, 2004.
143. Gallagher KA, Liu ZJ, Xiao M, et al: Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 117: 1249-1259, 2007.
144. Thum T, Hoeber S, Froese S, et al: Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res 100: 434-443, 2007.
145. Thum T, Tsikas D, Stein S, et al: Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 46: 1693-1701, 2005.